Nasal and Sinus Cancer
52 clinical trials
0 cell line models
9 approved drugs
Nasal and Sinus Cancer
Molecular Synopsis
Drugs and clinical candidates

9 drugs have received FDA approval for Nasal and Sinus Cancer:

  • Arsenic Trioxide
  • Bosutinib Monohydrate
  • Dasatinib
  • Daunorubicin Hydrochloride
  • Imatinib Mesylate

28 drugs have a clinical trial registered for Nasal and Sinus Cancer.

3 compounds have been tested in Nasal and Sinus Cancer (3 <= 500nM potency).

Sources:,, ChEMBL.

Clinical trials
There are 52 clinical trials for Nasal and Sinus Cancer, 39 of which have one or more drug interventions, 13 with no drug intervention.
Cell line models

There are 0 Cell Line Models for Nasal and Sinus Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from mesh condition terms to Nasal and Sinus Cancer:
  • Paranasal Sinus Neoplasms
  • Nose Neoplasms
The following terms have been mapped from to Nasal and Sinus Cancer:
  • Acute promyelocytic leukemia (APL) in patients whose cancer has a certain type of chromosome mutation that affects the PML gene and RARA gene. It is used:In adults with newly diagnosed APL that is low risk
  • Acute lymphoblastic leukemia in adults and children that is Philadelphia chromosome positive. In adults, it is used for disease that has recurred (come back) or is refractory (does not respond to treatment). In children, it is used as the first treatment after the disease is diagnosed
  • Acute myeloid leukemia (AML). It is used with cytarabine and daunorubicin hydrochloride in newly diagnosed adults whose cancer has a mutation in the FLT3 gene
  • In adults with chronic phase CML that is newly diagnosed
  • Multiple myeloma in patients who have just been diagnosed with the disease